HCA Healthcare is leveraging its multi-year resiliency program focused on digital transformation and shared services to control unit costs and maintain profitability despite facing a $1.0-$1.2 billion headwind from health insurance exchange disenrollment in 2026. The company achieved flat year-over-year cost per admission in Q2 and targets 4-6% long-term adjusted EBITDA growth. Peers Tenet Healthcare and Universal Health Services are similarly pursuing operational efficiency initiatives.

Ensign Group (ENSG) is benefiting from rising occupancy, patient volumes, and skilled-mix revenue growth in the post-acute care market. The company completed 25 acquisitions in H1 2026, adding 3,109 beds, and its Standard Bearer real estate segment generated $44.1 million in rental revenues. With a Zacks Rank #2 (Buy) rating and raised 2026 EPS guidance to $7.75-$7.85, ENSG faces headwinds from government reimbursement risks and rising expense growth.

Large-cap stocks in software, electric vehicles, data centers, and healthcare faced significant pressure last week due to weak guidance, regulatory concerns, rising bond yields, and competitive risks. Technology and China-linked companies led the declines, with ten major stocks experiencing notable losses ranging from 4.96% to 18.28%.

Tenet Healthcare reported mixed Q1 2026 results with adjusted EPS of $4.82 beating consensus of $4.18, but sales of $5.37B missed expectations of $5.39B. The company blamed unfavorable payer mix from lower exchange admissions and winter storms for soft performance. Despite this, Tenet raised full-year adjusted earnings guidance to $16.38-$18.68 per share and reaffirmed sales guidance of $21.5-$22.3B. The stock declined 5.95% on the news.

Tenet Healthcare reported strong Q4 2025 results with sales of $5.527 billion (up 8.9% YoY) and adjusted EPS of $4.70 (up from $3.44), beating consensus estimates. The company saw growth across both hospital operations and ambulatory segments, driven by higher acuity cases and favorable payer mix. For 2026, Tenet expects revenue guidance of $21.5-$22.3 billion and adjusted EBITDA of $4.485-$4.785 billion, with shares rising 6.73% on the news.

Tenet Healthcare demonstrates strong financial performance with impressive Q2 2025 results, featuring revenue growth, margin expansion, and strategic focus on ambulatory care. The company shows potential for growth despite potential future Medicaid policy challenges.

Tenet Healthcare reported strong Q2 2025 earnings, with adjusted EPS of $4.02, exceeding analyst expectations. The company saw revenue growth in Ambulatory Care and raised its full-year financial guidance, driven by margin improvements and strategic portfolio shifts.

Several large-cap companies, including Duolingo, CoreWeave, and DexCom, saw significant gains last week due to strong earnings, sales guidance, and analyst upgrades.

The global plastic fencing market is expected to grow significantly due to rising demand from the residential and commercial construction industries, as well as the increasing adoption of recycled plastics in fencing products.

Tenax Therapeutics, a Phase 3 pharmaceutical company, announced its participation in the Guggenheim SMID Cap Biotech Conference, where its President and CEO will present in a fireside chat.

The White House has ordered a temporary freeze on all federal grants and loans, putting $3 trillion in funding under scrutiny and threatening industries like clean energy, defense, and healthcare.

The article discusses the evolving landscape of rare cardiovascular diseases, including Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy. It highlights the challenges in diagnosis and treatment, as well as the growing market size and pipeline of new therapies for these conditions.